MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: Life Sciences, Medical Devices & Health Information Technology
2025: Top 10 U.S. Biopharma Clusters 2025
Massachusetts
*Industry: Massachusetts
Cogent Biosciences, Inc. (NASDAQ: COGT), formerly, Unum Therapeutics (UMRX)*
Organization & Developments: Cogent Biosciences
Parents
Cogent Biosciences, Inc. (NASDAQ: COGT), formerly, Unum Therapeutics (UMRX)*
Children
*Unum Therapeutics Inc., a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient’s immune system to cure cancer.
2014: Cellular Immunotherapy & Unum Therapeutics: Out of Many, One
2019: FDA puts Unum T cell therapy trial on hold after adverse events
2020: Unraveling The Investment Case For Unum Therapeutics
2020: Unum Therapeutics Announces Company Name Change to Cogent Biosciences, Highlights Recent Scientific and Operational Progress
2022: Cogent Biosciences: What's Ahead_seekingalpha.com
2024: Cogent Biosciences: Need To Wait For More Data For Adequate Differentiation
2024: Cogent Biosciences: Stock Soars On Cash Injection Ahead Of Major Data Catalyst
2025: 3 Biotech Stocks With Notable Insider Buying
2025: Cogent Biosciences Secures Massive $200M Funding to Accelerate Bezuclastinib Development
2025: Cogent Biosciences sets key 2025 milestones for drug trials
2025: Cogent Biosciences: Buy The Pullback For Bezuclastinib's 2025 SM And GIST Data
2025: Cogent surges as bezuclastinib meets key goal in phase 2 mastocytosis tria
2026: COGT SWOT Analysis: Financial Challenges and Growth Potential Re
Jumps
Finance & Acquisitions: Cogent Biosciences
Key People: Cogent Biosciences